A diquafosol ophthalmic solution containing chelating agent with a concentration of 0.0001~1%(w/v) restrains the formation of insoluble precipitates observed during storage of ophthalmic solution containing diquafosol and the lowering of filtration property in the production process (filtration/sterilization process). By comparing with the ophthalmic solution containing diquafosol but not chelating agent, it is also confirmed that the diquafosol ophthalmic solution containing chelating agent shows a low eye irritation and an improved ability to retain the effect during storage. Accordingly, the present invention, wherein a low eye-irritation and an improved ability to retain the effect during storage have been also confirmed, has stable physiochemical property in the course of production, distribution and storage by patients. In particular, the diquafosol ophthalmic solution containing chelating agent is able to suppress the reduction of filterability in the production process (filtration/sterilization process), and, therefore, enables efficient filtration/sterilization in the production process that will be helpful to reduce production costs.含有濃度0.0001~1%(w/v)之螯合劑的迪夸弗索點眼液，可抑制於迪夸弗索點眼液所確認之保存時不溶性析出物之產生、以及製造過程(過濾滅菌過程)中過濾性之降低。又，亦已確認含有螯合劑之迪夸弗索點眼液，相較於未含有螯合劑之迪夸弗索點眼液，其眼刺激性減輕及保存效力增強。因此，本發明除於製造及流通過程、以及藉由患者之保存過程中具有安定之物理化學性質之外，亦已確認其眼刺激性減輕及保存效力增強。尤其，含有螯合劑之迪夸弗索點眼液，由於可抑制在製造過程(過濾滅菌過程)中過濾性之降低，故可於製造過程中進行有效率之過濾滅菌，而有助於抑制製造成本。
